{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
CASI Pharmaceuticals, Inc.
CASI Pharmaceuticals Forms Golden Cross, Signaling Potential Bullish Breakout
CASI Pharmaceuticals, Inc. has recently achieved a Golden Cross, a technical event indicating a potential shift in momentum. While the stock has shown a daily performance increase, its one-year performance remains significantly down. The implications of this development may influence future trading activity and investor sentiment.
Is CASI Pharmaceuticals, Inc. technically bullish or bearish?
As of August 4, 2025, CASI Pharmaceuticals, Inc. shows a mildly bearish technical trend, with mixed indicators suggesting underperformance compared to the S&P 500, including a 1-year return of -73.67%.
Is CASI Pharmaceuticals, Inc. overvalued or undervalued?
CASI Pharmaceuticals, Inc. is currently considered overvalued and rated as risky due to negative financial metrics, including a Price to Book Value of -3.67 and a year-to-date return of -56.54%, significantly underperforming the S&P 500.
Is CASI Pharmaceuticals, Inc. technically bullish or bearish?
As of May 27, 2025, CASI Pharmaceuticals, Inc. has shifted to a bearish trend with moderate strength, supported by bearish signals from the MACD, RSI, moving averages, and underperformance relative to the S&P 500.
Who are in the management team of CASI Pharmaceuticals, Inc.?
As of March 2022, the management team of CASI Pharmaceuticals, Inc. includes Dr. Wei-Wu He as Executive Chairman and CEO, along with independent directors Mr. James Huang, Mr. Franklin Salisbury, Dr. Rajesh Shrotriya, Dr. Y. Alexander Wu, and Mr. Quan Zhou.
What does CASI Pharmaceuticals, Inc. do?
CASI Pharmaceuticals, Inc. is a micro-cap biopharmaceutical company focused on developing and commercializing cancer therapeutics. As of March 2025, it reported net sales of $6 million and a net loss of $11 million, with a market cap of $23.38 million.
How big is CASI Pharmaceuticals, Inc.?
As of Jun 18, CASI Pharmaceuticals, Inc. has a market capitalization of 23.38 million and reported net sales of 31.37 million, with a net profit loss of 40.47 million. Shareholder's funds were 1.85 million, and total assets were 53.67 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
